Rzeszow

• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-504735-41-00 5 2024-03-05 Moderately to Severely Active Crohn's Disease
• A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting
  2023-505251-43-00 5 2024-02-28 Primary Biliary Cholangitis
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul … Recruiting
  2023-504863-17-00 5 2024-02-21 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV Recruiting
  2023-509046-36-00 5 2023-04-26 Active Ulcerative Colitis (UC) or Crohn's disease (CD)
• FORMA – a multicentre randomized-controlled trial to evaluate the efficacy and safety of ketoanalogues of essential amino acids in prophylax … Recruiting
  2024-517880-22-00 5 2023-01-04 Protein-energy wasting in nephrotic syndrome
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting
  2023-506239-14-00 5 2022-12-13 Ulcerative Colitis
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria … Recruiting
  2022-500408-22-00 5 2022-09-14 Plaque Psoriasis
• A study of Vedulizumab in Children and Teenagers with Moderate to Severe Crohn's Disease (CD) Recruiting
  2023-509045-13-00 5 2022-02-28 Moderately to severely active Crohn's disease (CD)
• A multicentre study evaluating the safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtP … Recruiting
  2024-518509-17-00 4 2022-01-10 Acute ischemic stroke
• Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with iron deficiency anemia (IDA) or who … Recruiting
  2024-516264-28-00 5 2019-09-03 Iron Deficiency Anemia (IDA)
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• A Study of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis (BROADEN2) Ended recruitment
  2025-522370-36-00 4 2026-02-02 Moderate to Severe Atopic Dermatitis
• A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Sub … Ended recruitment
  2022-501349-64-00 4 2026-01-12 Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended recruitment
  2024-515438-33-00 5 2026-01-12 Alopecia areata
• A study to find if tibulizumab works and how safe it is in participants with systemic sclerosis Ended recruitment
  2024-519335-42-01 4 2025-12-22 Systemic Sclerosis
• A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Ended recruitment
  2024-517980-22-00 4 2025-12-10 Multiple Sclerosis (MS)

Showing 121–144 of 329 trials